Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
PDX1328 Tivantinib
1.0
MET
RTK
 -0.3964 0.27687
HCC70 Taxol
0.031623
Chemo
Chemotherapy
 -0.3961 0.59071
HCC1954 Taxol
1.0
Chemo
Chemotherapy
 -0.3961 0.69698
PDX1328 AZD7762
1.0
CHK1/2
Cell cycle
 -0.3953 0.26307
MDA-MB-361 Volasertib
0.01
PLK
Cell cycle
 -0.3949 0.36332
MDA-MB-134-VI Torin2
0.031623
mTOR/ATM/ATR
PI3K/mTOR
 -0.3945 0.21493
PDX1328 Taxol
0.01
Chemo
Chemotherapy
 -0.3931 0.29059
PDX1258 Buparlisib
10.0
pan PI3K
PI3K/mTOR
 -0.3924 0.46482
SUM149PT Luminespib
1.0
HSP90
Misc
 -0.3912 0.70780
HCC1419 Dinaciclib
0.1
pan CDK
Cell cycle
 -0.3905 0.32451
SUM149PT AZD7762
3.1623
CHK1/2
Cell cycle
 -0.3899 0.67425
CAL-51 Buparlisib
10.0
pan PI3K
PI3K/mTOR
 -0.3883 0.61074
HCC1500 Topotecan
0.1
Topo I
Chemotherapy
 -0.3879 0.20010
SUM1315MO2 Volasertib
0.31623
PLK
Cell cycle
 -0.3877 0.52524
HME1 A-1210477
3.1623
Mcl-1
Misc
 -0.3871 0.56207
PDXHCI002 Dinaciclib
0.1
pan CDK
Cell cycle
 -0.3866 0.51109
MDA-MB-468 Buparlisib
3.1623
pan PI3K
PI3K/mTOR
 -0.3860 0.72884
HCC1419 Neratinib
1.0
EGFR/HER2
RTK
 -0.3858 0.36554
HCC70 Taselisib
3.1623
PI3Ka, g, d
PI3K/mTOR
 -0.3852 0.41345
MDA-MB-231 Vorinostat
10.0
HDAC
Misc
 -0.3848 0.58110
HCC1954 Tivantinib
3.1623
MET
RTK
 -0.3846 0.64290
HME1 Etoposide
10.0
Topo II
Chemotherapy
 -0.3838 0.67631
CAL-85-1 Luminespib
1.0
HSP90
Misc
 -0.3836 0.57253
BT-20 Etoposide
10.0
Topo II
Chemotherapy
 -0.3834 0.56500
MDA-MB-468 Neratinib
3.1623
EGFR/HER2
RTK
 -0.3825 0.59938